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Stereoselectivity in drug metabolism can not only inﬂuence the pharmacological activities, tolerability,
safety, and bioavailability of drugs directly, but also cause different kinds of drug–drug interactions. Thus,
assessing stereoselectivity in drug metabolism is of great signiﬁcance for pharmaceutical research and
development (R&D) and rational use in clinic. Although there are various methods available for assessing
stereoselectivity in drug metabolism, many of them have shortcomings. The indirect method of chro-
matographic methods can only be applicable to speciﬁc samples with functional groups to be derivatized
or form complex with a chiral selector, while the direct method achieved by chiral stationary phases
(CSPs) is expensive. As a detector of chromatographic methods, mass spectrometry (MS) is highly sen-
sitive and speciﬁc, whereas the matrix interference is still a challenge to overcome. In addition, the use of
nuclear magnetic resonance (NMR) and immunoassay in chiral analysis are worth noting. This review
presents several typical examples of drug stereoselective metabolism and provides a literature-based
evaluation on current chiral analytical techniques to show the signiﬁcance and challenges of stereo-
selectivity assessing methods in drug metabolism.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
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In clinic, chiral drugs that contain at least one chiral center are
widely used and play an important role in treating human dis-
eases. Over half of therapeutic drugs are chiral, and the majority of
them are administered as racemates, mixtures containing equal
proportions of (R)- and (S)-enantiomers [1,2]. Owing to the dif-
ferent three-dimensional conﬁgurations of enantiomers, although
the individual drug enantiomers present identical physicochem-
ical properties in an achiral environment, they generally show
different pharmacological activities in a chiral environment, such
as in the body [3]. The phenomenon that only one enantiomer is
effective against a particular disease while the other enantiomer
has different pharmacological activity or even toxicity exists
commonly in many chiral drugs [4,5]. For example, (R)-ﬂurbipro-
fen can modulate γ-secretase and has the potential to treat the
symptoms of Alzheimer's disease, while (S)-ﬂurbiprofen is more
toxic because it can inhibit cyclooxygenase directly [6,7].
Thus, there has been an increased awareness of the effects of
stereoselectivity in drug metabolism. Developing single en-
antiomer drugs has been a tendency in recent years due to their
advantages, i.e., lower administered dose, simpler dose–response
relationship and lower toxicity [3,8]. Among the 127 new mole-
cular entities (NMEs) approved by U.S. Food and Drug Adminis-
tration (FDA) between January 2010 and December 2014, chiral
NMEs were the major component (81 (64%) of the 127 NMEs), and
among the 81 chiral NMEs, single enantiomers were the great
majority (Fig. 1) [9].
In this case, many people doubt that the importance of ste-
reoselectivity assessing in drug metabolism is limited and will
steadily decline. However, it is essential to assess stereoselectivity
in drug metabolism before we decide to develop a single-en-
antiomer or racemic drug. Nowadays, most countries' govern-
ments have stipulated that research on enantiomers should be
carried out in pharmacology, toxicology and metabolism sepa-
rately during the development of new drugs. Chiral drugs can be
produced as racemates only if there is no obvious effect on the
efﬁcacy or toxicity when the two enantiomers coexist, because
racemic drugs require lower costs of production but have more
risks of application than single-enantiomer drugs. In addition,
since many old drugs are still given as racemates, it is essential to
monitor the blood concentration of each enantiomer respectively
in therapeutic drug monitoring. Here, we review several typical
examples of drug stereoselective metabolism from the aspects ofFig. 1. The chirality of NMEs. The percentage (shown on the y-axis) and number
(shown above the bars) of FDA-approved NMEs according to the chirality of the
NME are shown for the 2010–2014 period.fundamentals, types, and effects in order to further show that
stereoselectivity assessing in drug metabolism is of great sig-
niﬁcance for pharmaceutical research and development (R&D) and
the rational use in clinic. Additionally, current chiral analytical
techniques, including high-performance liquid chromatography
(HPLC), gas chromatography (GC), supercritical ﬂuid chromato-
graphy (SFC), capillary electrophoresis (CE), nuclear magnetic re-
sonance (NMR), and immunoassay, are evaluated. Although these
techniques have made great contributions to stereoselectivity as-
sessing, many challenges have not been overcome.2. Stereoselectivity in drug metabolism
Among all pharmacokinetic processes, metabolism is the most
stereoselective process due to the involvement of the enzymatic
system, such as cytochrome P450 enzymes (CYPs) and uridine 5′-
diphospho (UDP)-glucuronosyltransferases (UGTs). CYPs and UGTs
are the major determinants during the metabolism of most drugs
on the market [10,11]. CYPs catalyze the oxidative reactions in
Phase I metabolic reactions, while UGTs catalyze the glucur-
onidation reactions in Phase II metabolic reactions. They have a
wide range of substrates and present great stereochemical sensi-
tivity, i.e., different afﬁnities and/or reactivities for two en-
antiomers of a chiral drug.
According to where the chiral discrimination in drug metabo-
lism occurs, metabolic stereoselectivity can be classiﬁed into
substrate stereoselectivity (the differential metabolism of two or
more stereoisomeric substrates), product stereoselectivity (the
differential formation of two or more stereoisomeric metabolites
from a single substrate) and their combination, and substrate–
product stereoselectivity, which contains a unique phenomenon,
chiral inversion [12]. Some examples [13–23] showing stereo-
selectivity in drug metabolism are presented in Table 1.
2.1. Substrate stereoselectivity
Substrate stereoselectivity refers to the phenomenon that two
enantiomers are metabolized at different rates in a reaction that
neither creates nor adds a stereogenic element when forming the
metabolites [12]. Enantiomers usually have different afﬁnities with
enzymes, which induces different metabolites and different me-
tabolic rates. Therefore, they often show different pharmacological
activities and elimination rates in the human body. In order to
minimize toxicity and reduce the total dose of an administered
drug, the majority of newly approved chiral drugs are not devel-
oped as racemates but as single enantiomers, which means that it
is essential to study the substrate stereoselectivity of a chiral NME
to decide which enantiomer should be produced.
The substrate stereoselectivity in drug metabolism is ex-
empliﬁed by the metabolism of a proton pump inhibitor, ome-
prazole (Fig. 2). The asymmetric sulfur of omeprazole generates
two enantiomeric forms, (S)- and (R)-omeprazole. Their main
routes of metabolism, i.e., sulfoxidation and hydroxylation, have
been shown to be mediated via CYP3A4 and CYP2C19, respectively
[15,16]. The predominant metabolism for the (S)-enantiomer is
catalyzed by CYP3A4, which generates omeprazole sulfone. The
(R)-enantiomer is metabolized primarily by CYP2C19, which gen-
erates hydroxyomeprazole and a minor metabolite, 5-O-des-
methylomeprazole (Fig. 2) [24,25]. As a consequence of the
Table 1
Stereoselectivity in drug metabolism.
Drug Main enzymatic metabolic pathway Metabolic enzyme (Vmax(R)/(S)) Ref.
Ifosfamide 4-Hydroxylation CYP2B1(0.59), CYP2B6(0.12), CYP3A4(2.55), CYP3A7(1.36) [13]
N2-Dechloroethylation CYP2B6(0.07), CYP3A4(6.69)
N3-Dechloroethylation CYP2B6(2.41), CYP3A4(0.06)
N-Dechloroethylation CYP2B1(1.60), CYP2B6(1.07), CYP3A4(0.21), CYP3A7(0.85)
Methadone N-Dealkylation CYP2B6(1.40), CYP3A4(2.75), CYP2C19(0.93) [14]
Omeprazole 5-Hydroxylation CYP2C19(7.57) [15,16]
Sulfoxidation CYP3A4(0.38)
5′-O-Demethylation CYP2C19(0.15)
Warfarin 7-Hydroxylation CYP2C9(o0.1), CYP2C19(410) [17]
6-Hydroxylation CYP1A2(410)
8-Hydroxylation CYP2C9(o0.1), CYP2C19(410)
4′-Hydroxylation CYP3A4(o0.1)
Verapamil N-Demethylation CYP2C8(0.46), CYP3A4(0.73), CYP3A5(1.20), CYP3A7(0.51) [18,19]
N-Dealkylation CYP2C8(1.00), CYP3A4(1.27)
Metoprolol O-Demethylation CYP2D6(1.72) [20]
Phenprocoumon 4′-Hydroxylation CYP2C9(3.30), CYP3A4(0.90) [21]
6-Hydroxylation CYP2C9(0.65), CYP2C19(0.80), CYP3A4(0.64)
7-Hydroxylation CYP2C9(2.42), CYP2C19(0.52), CYP3A4(0.17)
Formoterol Glucuronidation UGT(0.61) [22]
Salbutamol Sulfation M-PST(0.91) [23]
CYP: Cytochrome P450 enzyme, UGT: Uridine 5′-diphospho (UDP)-glucuronosyltransferase, PST: Phenolsulfotransferase.
Fig. 2. The structure of omeprazole and its metabolites (the atom marked * is the
chiral center).
Fig. 3. The structure of methylphenobarbital (the atom marked * is the chiral
center).
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vailability of two enantiomers is signiﬁcant. As Abelö et al. [16]
reported, the formation rate constant (intrinsic clearance) was 14.6
and 42.5 mL/min/mg protein for (S)- and (R)-omeprazole, respec-
tively, which indicated that (S)-omeprazole was cleared more
slowly than R-omeprazole in vivo. Thus, esomeprazole, the (S)-
enantiomer of omeprazole was developed as an individual drug
and has demonstrated signiﬁcantly greater efﬁcacy than omepra-
zole, while the tolerability and safety of esomeprazole were
comparable to those of omeprazole [26].
Methylphenobarbital (MPB) (Fig. 3) is a drug for convulsions.
The (R)-MPB was extensively hydroxylated, with an average of
49.56% of that enantiomer being converted to (R)-4-hydroxy-MPB,
while only 7.16% of the (S)-MPB was converted to the corre-
sponding hydroxy metabolite [27]. The extensive hydroxylation of(R)-MPB resulted in rapid elimination of this enantiomer, whereas
the (S)-MPB was eliminated very slowly [27].
2.2. Product stereoselectivity
Product stereoselectivity usually occurs in the substrates con-
taining an element of prostereoisomerism (often a center of pro-
chirality) during the reduction of ketone, the hydrogenation of
carbon–carbon double bond, the oxygenation of prochiral sub-
stituent group, Phase II metabolic conjugated reaction, etc. [12].
During this metabolism, the prostereoisomerism is usually trans-
formed into one conﬁguration metabolite rather than the other.
Therefore, although the drugs are achiral or pure enantiomer, their
different conﬁguration metabolites are produced at different rates
by different enzymes. Considering interindividual variability or
species differences of enzymes, product stereoselectivity may in-
duce the different pharmacological activities in different people or
species. As most of the drugs approved recently have a center of
asymmetry and the majority are single enantiomers, product ste-
reoselectivity in drug metabolism draws increasing attention.
Phenytoin (PPH, Fig. 4), a frequently prescribed drug for the
treatment of epilepsy, possesses the prochiral para-hydroxylation.
It is catalyzed by CYP2C9 and CYP2C19, and primarily metabolized
to 5-(4′-hydroxyphenyl)-5-phenylhydantoin (p-HPPH), a mixture
of (R)-p-HPPH and (S)-p-HPPH. As Argikar et al. [28–30] reported
that the formation of HPPH from PPH was mediated exclusively by
CYP2C9 and 2C19, with CYP2C9 playing the major role. PPH cat-
alyzed by CYP2C9 was more inclined to form (S)-p-HPPH while
PPH catalyzed by CYP2C19 did not have any tendency to form (R)-
p-HPPH or (S)-p-HPPH. Therefore, the genetic polymorphisms of
CYP2C9 and CYP2C19 will induce the different (S)/(R)-p-HPPH
formation ratios.
Bufuralol (BF, Fig. 5) is a nonselective β-adrenoceptor blocking
agent, which has a chiral center in its molecule, yielding the eu-
tomer, 1″S-BF, and the distomer, 1″R-BF. One of the metabolic
pathways of BF is 1″-hydroxylation of an ethyl group, which in-
troduces another chiral center into the BF molecule and yields four
1″-OH-BF diastereomers [31]. In ordinary human liver, this meta-
bolic reaction shows a clear product stereoselectivity of 1″S-OH-
BF41″R-OH-BF from either BF enantiomers or racemates cata-
lysed by the determinant enzyme CYP2D6. However, in poor
CYP2D6 liver, it shows a product stereoselectivity of 1″S-OH-
Fig. 4. The structure of phenytoin and its metabolites.
Fig. 5. The structure of bufuralol and its metabolites.
Fig. 6. The structure of thalidomide (the atom marked * is the chiral center).
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different β-adrenoceptor blocking activities among the four 1″-
OH-BF diastereomers, interindividual variability of pharmacologi-
cal activities often occurs in different humans.
2.3. Substrate–product stereoselectivity
As the name indicates, substrate–product stereoselectivity re-
fers to the metabolism that contains both substrate stereo-
selectivity and product stereoselectivity, which means that the
metabolites of racemates are more complex. Besides, substrate–
product stereoselective metabolism contains chiral inversion,
which makes no sense of producing single enantiomers.
A particularly instructive example of chiral inversion can be
found in the metabolism of thalidomide (Fig. 6). Thalidomide has a
chiral center and exists as racemates of (R)- and (S)-enantiomers.
The (R)-enantiomer contains a sedative effect, while the (S)-en-
antiomer causes fetal malformations [32]. Scientists have made an
attempt to separate the racemates to a pure enantiomer. However,
whether animals were administered pure (R)-enantiomer or pure
(S)-enantiomer, both hypnotic and teratogenic effects existed in
animals, which suggested that single enantiomer may convert into
the other in vivo [33]. Accordingly, there is no rationale for de-
veloping a single-enantiomer drug for thalidomide and other si-
milar drugs.
3. Stereoselective analytical methods
The stereoselective metabolic process is so complex that onlythe methods of chiral recognition can make metabolic pathway
clear. In order to know the extremely complex chiral inversion and
chiral interactions, it is also necessary to establish a stereospeciﬁc
method to analyze the individual enantiomer in biological samples
such as plasma, urine, tissues and microsome.
As stereoselective analytical techniques have been developed,
the accurate and reproducible determination of both drugs and
metabolites in biological media has become possible. Recently,
various methods are available for chiral bioanalytical assay, such as
HPLC, GC, SFC, CE, NMR, and immunoassay. Among these techni-
ques, chiral chromatography (HPLC, GC, SFC) and electrophoresis
(CE) coupled with ultraviolet (UV), ﬂuorescence (FL) and mass
spectrometry (MS) detection are still the predominant analytical
tools [34]. A comparison of these general techniques [35–46] for
the steroselective analysis of drugs and metabolites is presented in
Table 2.
3.1. HPLC
HPLC is still the most utilized technique for chiral separations
in drug metabolism studies, which can be performed indirectly or
directly [3,47]. The indirect method is performed using chiral de-
rivatization reagents (CDRs) while the direct method is performed
by chiral mobile phase additives (CMPAs) or chiral stationary
phases (CSPs) [3]. After the separation, enantiomers are usually
detected by UV, FL or MS.
3.1.1. CSPs
CSPs is a preferred method due to its inherent advantages such
as high speed, high reproducibility and ﬂexibility during the ana-
lysis of enantiomers in complex mixtures [34,48]. With the de-
velopment of CSPs, many kinds of CSPs have been successfully
used in the assays of chiral drugs and their metabolites in plasma,
urine and liver microsomal fractions [34]. Currently, numerous
commercial CSPs are available. According to their materials, CSPs
can be divided into many types, such as proteins CSPs, amino acids
CSPs, cyclodextrin CSPs, polysaccharide-based CSPs, crown ether
CSPs, macrocyclic antibiotic CSPs, chiral ion- and ligand-exchange
CSPs, and molecular imprinted polymer (MIP) CSPs. Poly-
saccharide-based CSPs and macrocyclic antibiotic CSPs are the
most important and popular CSPs employed in HPLC [36,47,48].
3.1.1.1. Polysaccharide-based CSPs. Polysaccharide-based CSPs in-
clude polysaccharide derivatives CSPs (such as ChiralCel OJ, OA,
OB, OK, CA-1), cellulose carbamate derivatives (such as ChiralCel
OD, OC, OG, OF) and amylose CSPs (such as ChiralPak AD, AS)
[49,50]. Polysaccharide-based CSPs can be divided into coated and
immobilized columns, which may exhibit different selectivities,
because the conformation of the polymer is inﬂuenced by how the
stationary phase is attached to the packing material [51]. Poly-
saccharide-based CSPs have their own features and are used for
separation of different types of racemic compounds [52]. The
polysaccharide-based CSPs have many important advantages such
as large loading sample size, their ease to be superseded and
functionalized, and a wide range of applications which have
earned polysaccharide-based CSPs a great reputation in the ﬁeld of
chiral resolution [53]. Recently, an innovative method for the
Table 2
The comparison of general techniques for the steroselective analysis of drugs and their metabolites.
Technique Application Complexity Analysis speed Efﬁciency Cost Ref.
HPLC CDR Samples that have the functional group to be deriva-
tized with
Moderate Time consuming derivatization Low Low [35–37]
CMPA Samples that can generate diastereomer compounds
with CMPAs
Simple Long balance process in the
column
Moderately high Moderately high
CSP Majority samples Simple Fast High High
GC CDR Samples that can be gasiﬁed Complex Slow Low Low [38,39]
CSP Simple Fast High High
SFC Thermal instability and low volatile substances Simple Very fast Very high Low [40,41]
CE Majority samples Simple Very fast High Low [42,43]
NMR CDA Samples that have groups reacted with CAD Complex Fast High Low [44,45]
LSR Ester compounds Simple Fast High High
CSA Alcohols, amines, carboxylic acids, etc. Simple Fast High Low
Immunoassay Preliminary screening Simple Fast High – [46]
CDR: Chiral derivatization reagent, CMPA: Chiral mobile phase additive, CSP: Chiral stationary phase, CDA: Chiral derivatizing agent, LSR: Lanthanide shift reagent, CSA:
Chiral solvating agent.
Z. Shen et al. / Journal of Pharmaceutical Analysis 6 (2016) 1–10 5simultaneous determination of guaifenesin and ketorolac tro-
methamine enantiomers in plasma samples has been developed
using amylose-2 as its chiral selector under the normal phase
mode and using ornidazole as its internal standard [53]. This
method is easy, reliable, and can be applied to the simultaneous
quantitative analysis of drug enantiomers in other clinical samples.
Yu et al. [54] developed a method to separate and quantify the
enantiomers of a new potent selective 5-HT1B/1D receptor partial
agonist, (S)-zolmitriptan, and its antipode in rat liver microsomes
using a narrow-bore enantioselective normal phase Chiralpak AD-
H column (250 mm0.46 mm) with hexane–isopropanol–trie-
thylamine as mobile phase and ﬂuorescence detection. However, it
should be noted that we should not use the eluents containing
hydrochloric ethers, which will strip cellulose from the surface of
silicon.
3.1.1.2. Macrocyclic antibiotic CSPs. Macrocyclic antibiotic CSPs in-
clude macrocyclic glycoprotein CSPs (such as teicoplanin, vanco-
mycin) and ansamycin CSPs. Compared with other antibiotics,
macrocyclic glycopeptides are more popular because of their unique
versatility and broad selectivity [51]. Macrocyclic glycopeptides
have multiple stereogenic centers and various functional groups
which can provide stereoselective interactions with enantiomers
[55]. Hefnawy et al. [56] developed and validated a method to de-
termine the enantiomers of bisoprolol in human plasma using a
teicoplanin macrocyclic antibiotic CSP known as Chirobiotic T with
a polar ionic mobile phase consisting of methanol–glacial acetic
acid–triethylamine and ﬂuorescence detection. The human plasma
sample was treated with solid phase extraction prior to HPLC ana-
lysis. Compared with Suzuki's method [57] achieved by a ChiralCel
OD column and ﬂuorescence detection, Hefnawy's method took less
analysis time and gained a higher percentage of recovery from
biological samples.
3.1.1.3. MIP CSPs and new CSPs. MIP is a material with high se-
lectivity for speciﬁc molecules. It is made using a promising
technique, molecular imprinting. Speciﬁcally, MIP is a speciﬁc ar-
tiﬁcial receptor that is prepared by a polymerization reaction of a
template molecule (target molecule) and a functional monomer
(s) followed by removing the template molecules to leave behind
the permanent template grooves [58]. MIPs show high afﬁnity and
selectivity for their template molecule and have higher physical
strength, robustness, resistance to elevated pressure and tem-
perature, and inertness against various chemicals compared to
biological media such as proteins and nucleic acids [58]. Therefore,
when an enantiomer is used as the template, the produced MIP
will show capability of enantiomeric recognition between the pairof enantiomers [59]. Due to these excellent properties, MIP has
been largely used in chiral separations as stationary phases for
HPLC, capillary electro chromatography, etc. [60–62]. However, no
literature reports that MIP CSPs are used in assessing stereo-
selectivity in drug metabolism.
In addition, novel CSPs continue to be introduced to the mar-
ket, such as the zwitterionic phases and new immobilized crown-
ether phases [63–65]. Geditz et al. [66] successfully separated
meﬂoquine (þ)- and ()-enantiomers and the carboxy metabolite
in dried blood spots using a quinidine-based zwitterionic chiral
stationary phase column, CHIRALPAKs ZWIX(). However, chiral
HPLC still lacks a CSP that can operate in all modes for separation
of enantiomer molecules with different properties. Besides, due to
the emergence of ultra high-performance liquid chromatography,
small grain sizes of CSPs are also worth noting in the future [67].
3.1.2. Chiral mobile phase additives (CMPAs)
Although the method of chiral stationary phase has inherent
advantages, it does cost more because it requires an expensive
chiral column, which cannot be universally used due to its strict
stereospeciﬁcity [68]. CMPAs can provide a simple and economical
method for the chiral separation in some cases, which employs a
conventional achiral column and mobile phase with a chiral se-
lector [69]. During the separation, the chiral additive interacts
with the enantiomers stereoselectively to achieve separation. The
CMPAs method is more versatile, cheaper, and more ﬂexible for
enantioseparations [68].
At present, a large number of CMPAs have been used in the
separation of chiral drugs. According to their separation mechan-
isms and structures, CMPAs can be divided into several types: li-
gand-exchangers, macrocyclic antibiotics, cyclodextrins, etc. [69].
Hatami and Farhadi [70] successfully separated ketoprofen en-
antiomers in human and rat plasma using hollow-ﬁber-based li-
quid-phase microextraction for sample treatment and vancomycin
as a CMPA with an achiral C8 column.
However, the CMPAs method also has many drawbacks. First,
the method is only suitable for limited compounds that can gen-
erate diastereomer with CMPAs. Second, the additive may inter-
fere with the detection, which may affect the analysis result. Third,
the balance process in the column is time-consuming and ad-
ditive-consuming.
3.1.3. Chiral derivatization reagents (CDRs)
Some chiral drugs present such weak chromatographic prop-
erties on CSP that they cannot be separated by direct method. In
these cases, CDRs may synthetically modify those drugs in order to
enhance the chromatographic signal or increase the
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of the target molecule and increases the molecular mass and hy-
drophobicity of the relatively small molecules in order to prevent
co-elution with high polar endogenous materials in complex ma-
trices such as plasma and urine [71,72].
A suitable CDR has to possess the following characteristics
[71,73]: (i) It should not cause any rearrangements or structural
alterations of compounds during the formation of the derivative;
(ii) The reagent should produce more than 95% complete deriva-
tives; (iii) It should not contribute to loss of enantiomer during the
reaction; (iv) It should produce a derivative that is stable and does
not interact with the column. Currently, various kinds of CDRs are
available, such as acylating reagents, thiocyanic acid, o-phtha-
laldehyde, esters reagents, etc. Nagao et al. [71] used novel chiral
derivatization reagents (PyT-C and PyT-N) for chiral metabolomics
identiﬁcation by HPLC and electrospray-ionization MS. The pro-
posed procedure using PyT-C and PyT-N has been applied to hu-
man saliva detections.
However, CDRs development is still in progress. In addition, the
indirect method is applicable for some speciﬁc samples with
functional groups to be derivatized or form complex with a chiral
selector. Moreover, the derivatization represents an additional
time consuming step and it has to be checked that no racemization
takes place under the reaction conditions.
3.1.4. HPLC with mass spectrometry (LC/MS)
MS has become a popular analytical tool because of its high
sensitivity and speciﬁcity compared to other detection techniques
such as UV and FL [71]. Chiral drugs and their metabolites are
usually at low levels in complex biological samples such as blood,
tissues and urine, so more selective and sensitive methods are
needed in their determination. Since the successful application of
atmospheric pressure ionization (API) and the advances of MS, the
combination of LC/MS has shown a signiﬁcant impact on meta-
bolite identiﬁcation, which supports drug metabolism studies of
chiral pharmaceuticals [74]. Nowadays, LC/MS has been widely
used in studies on chiral drug metabolism [75].
API is the most utilized ionization mode, including electrospray
ionization (ESI), atmospheric pressure chemical ionization (APCI),
and atmospheric pressure photoionization (APPI). API is a soft
ionization technique that only produces molecular ion peak and
can determine drugs in mixture directly. ESI is widely used in the
analysis of compounds that are polar, thermally unstable, or dif-
ﬁcult to be gasiﬁed [38,76]. Mass analyzer is the core of the mass
spectrometer. LC combined with quadrupole analyzers, ion-trap
analyzers, or high-resolution detectors such as time of ﬂight (TOF)
or Orbitrap analyzers becomes increasingly important in bioana-
lysis [33,77,78]. Ion-trap analyzers are useful in the qualitative
analysis of complex compounds [79,80]. TOF analyzers are suitable
for analyzing biological macromolecules such as protein [81,82].
Orbitrap analyzers coupled to reversed-phase LC represent the
most ubiquitous approach to both small molecule and proteomic
analyses [78,83–85].
Stable isotope labeled compound is popularly used as internal
standard in LC/MS. When one of the enantiomers is labeled by the
isotope, the enantiomers can be discriminated via MS on the basis
of their different molecular weights, regardless if they are sepa-
rated on a column or not. Yu et al. [86] developed a sensitive and
high-throughput HPLC–tandem mass spectrometry (LC–MS/MS)
method coupled with stable isotope labeling technology. This
method can simultaneously determine ﬂuoxetine and nor-
ﬂuoxetine enantiomers in a CYP2C9 incubation mixture and has
been used to study the metabolic interactions between ﬂuoxetine
enantiomers catalyzed by CYP2C9.
However, one of the most common problems for LC/MS en-
countered is the presence of matrix interference, which is usuallydifﬁcult to eliminate by adjusting HPLC conditions, modifying
sample preparation, or adding diethylamine or triethylamine [33].
3.2. Gas chromatography (GC)
Chiral GC, an important branch of chiral chromatography, can
be divided into CDRs and CSPs. Both methods are established for
applications based on the difference of the properties of en-
antiomers to achieve the separation.
GC with CSP is one of the important enantiomer-separating
approaches and utilized extensively. There are various types of GC
CSPs, such as peptide CSPs, bis-amides CSPs, chiral crown ether
CSPs, cyclodextrins CSPs, cellulose CSPs, and chiral-metal CSPs
[87,88]. Among these CSPs, cyclodextrins CSPs are the most widely
used CSPs in GC [35]. In recent years, GC CSPs have made some
progress. Chiral ionic liquids, a new type of GC CSP, has been de-
signed and utilized in the separation of chiral drugs based on
properties such as nonﬂammability, high thermal stabilities, and
variable polarities [89,90]. Existing literature has reported that
charged cyclodextrins as the chiral selectors resulted in sig-
niﬁcantly increased enantioselectivity and efﬁciency [91,92], but
no literature reports that these new types of GC CSPs can be used
in the analysis of chiral drug metabolism. However, the use of ionic
liquids for the analysis of chiral drug metabolism has become one
of the developmental frontiers.
In addition to the same requirements for CDRs and its deriva-
tization reactions of HPLC, CDRs and the generated corresponding
derivatives of GC are also required to be volatile to apply to GC
separation [42]. The commonly used chiral derivatization reagents
contain carboxylic acid derivatives, amines, alcohols, iso-
thiocyanates, etc. Tao et al. [93] developed a method for separating
chiral phenethylamine agents on an achiral capillary gas chroma-
tography by pre-column chiral derivatization with S-()-N-
(ﬂuoroacyl)-prolyl chloride. This method is simple, ﬂexible, and
economical for the analysis of chiral amine drug enantiomers in
biological ﬂuids and has been used to determine S-(þ)-metham-
phetamine in human forensic samples and analyze enantiomers of
amphetamine and fenﬂuramine in rat liver microsomes [93].
Like HPLC, GC/MS is widely used in studies on chiral drug
metabolism and the advantages of GC/MS coupled with stable
isotope labeling technology have been increasingly recognized
[94].
3.3. Supercritical ﬂuid chromatography (SFC)
Supercritical ﬂuid is a material at a temperature and pressure
above its critical point. SFC is a kind of chiral chromatographic
technique using supercritical ﬂuid as the mobile phase. CO2 is
chieﬂy used due to its high diffusivity and low viscosity. In addi-
tion, the solvation strength of CO2 can be enhanced by the addition
of polar organic modiﬁers [41,95].
Although HPLC remains a main choice for enantio-separations
and other separation techniques develop rapidly, SFC has become
a better choice, especially in bioanalysis, due to its fast analysis
speed, wide polarity compatibility, high column efﬁciency, low
cost, and environment-friendly mobile phase [96]. Recently, a
new method for the determination of tebuconazole in water and
zebraﬁsh was achieved by SFC-MS/MS [97]. Its mobile phase was
supercritical CO2 with a small amount of methanol, which is
simple, low in toxicity, and environmentally friendly. Its ﬂow rate
was 2.0 mL/min and its analysis time was much shorter than that
of HPLC. Moreover, CSPs of SFC were developed based on CSPs of
HPLC and GC, and many CSPs can be used for SFC without any
pretreatment [98]. In some cases, tandem arrangements (chiral–
chiral columns or achiral–chiral columns) can even increase the
total column efﬁciency and column capacity, which is beneﬁcial
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[99,100].
However, despite the progress in SFC for chiral separation and
determination, researchers still have relatively less interest in SFC
[40]. The main reason is that SFC lacks robustness and repeat-
ability. Moreover, though the addition of an organic modiﬁer in
the mobile phase (possibly with the addition of a third component
at low concentration) may afford elution of polar components, SFC
is not suitable for very polar drug [40].
3.4. Capillary electrophoresis (CE)
CE separation depends on the differential migration of solutes
in an electric ﬁeld and the driving forces are electrophoretic mi-
gration and electro-osmotic ﬂow [101]. CE has incomparable ad-
vantages in chiral drugs and their metabolites analysis. It can
analyze a drug and its phase II metabolites simultaneously and
presents the outstanding advantages of high resolving capability
and minimum solvent and reagent consumption, which is suitable
for analysis of small samples, such as infant blood samples and
in vivo microdialysis samples [102,103].
Similar to HPLC, CE prefers to employ CSPs as chiral selectors,
such as cyclodextrins, polysaccharides derivatives, macrocyclic
antibiotics and proteins. The detection of CE is usually achieved by
UV. Hamidi et al. [104] developed a method for chiral separation of
carvedilol in human plasma using CE coupled to ultraviolet diode
array detection. However, the sensitivity of UV is low because the
signal is directly related to an optical path length afforded by an
internal diameter of a capillary [105]. Thus, CE/MS has been re-
garded as a useful complementary analytical technique for the
proﬁling of (highly) polar ionogenic metabolites in biological
samples, especially in the ﬁeld of metabolomics [106]. A method
for identifying ecstasy and methadone in plasma was developed
using CE-electrospray ionization mass spectrometry, which was
successfully applied to quantitation of ecstasy and methadone in
real cases [107].
However, the surfactants in micellar electrokinetic chromato-
graphy and microemulsion electrokinetic chromatography, which
are used for the separation of neutral species, can cause several
problems in MS, including ion source contamination and baseline
noise [108]. CE still needs to be changed in many ways, and the
majority of these changes must be made to the chiral columns. The
repeatability of different capillary columns is one of the problems
hindering the development of the CE.
3.5. NMR
With the rapid development of high-resolution NMR instru-
ments, NMR has become a very useful tool in many ﬁelds. In the
study of chiral drugs, methods for determining the absolute con-
ﬁguration of chiral compounds require the structure parameters of
enantiomers, which can be acquired from NMR atlas, such as the
chemical shifts, the coupling constants, the relaxation rates, and
the areas of NMR absorption peak [109].
However, NMR spectroscopy fails to distinguish enantiomers in
the conventional achiral solvents because of the identical mag-
netic environment [44]. In order to use NMR in chiral analysis,
enantiomers must be converted to diastereomers, which permits
the enantio-discrimination and the precise measurement of en-
antiomeric excess [110]. Depending on the type of chiral auxiliary
reagents, three major methods can be used to determine en-
antiomers. The ﬁrst applies chiral derivatizing agents (CDAs),
which can transform enantiomers into stable diastereomeric de-
rivatives [111]. The second uses the chiral lanthanide shift reagent
(LSRs), which can interact with enantiomers and form coordina-
tion compounds [112]. The third employs certain chiral solvatingagents (CSAs), which can transform enantiomers into diamagnetic
and instable diastereomers [113]. The ﬁrst is an indirect method
while the others are direct methods.
CDAs are kinds of enantiomerically pure agents, such as (S)-
methoxyphenylacetic acid, phosphorus CDA, and organometallic
CDA. Compared with LSR or CSA, CDA has a more stationary nu-
clear magnetic signal [44,45]. However, there are more require-
ments for CDA. First, derivatizing agents should be optically pure,
which is not required for the method of CSA. Second, no racemi-
zation or kinetic resolution occurs during derivatization, while
racemization or kinetic resolution would not accrue in the method
of CSA. Third, the puriﬁcation of products can only use the non-
selective enrichment method. Therefore, CDAs are usually used in
the determination of enantiomeric purity in synthetic compounds,
but rarely applied to stereoselectivity assessing in drug metabo-
lism. LSRs are more widely used in the determination of ester
compounds than CDAs or CSAs because the ester compounds need
not be hydrolyzed before determination in LSR. However, most
LSRs cause excessive broadening of NMR peaks of chiral substrates
[44]. CSAs are more attractive in the analysis of chiral drugs and
their metabolites because the method of CSA usually does not
suffer from the broadening of the signals in the NMR spectrum
and the test enantiomers need not be derivatized and/or puriﬁed
prior to analysis. Pérez-Trujillo et al. [114] developed an 1H NMR-
based method for the differentiation and identiﬁcation of chiral
drug enantiomers (two enantiomers and one metabolite of ibu-
profen) in human urine via direct cosolvation with β-cyclodextrin.
This method does not require any pretreatment and has the po-
tential to be adapted for determining other enantio-speciﬁc me-
tabolic proﬁlings.
Furthermore, NMR can also be used in structure elucidation. In
pharmacological drug metabolite studies, the need for de novo
structure elucidation is becoming more frequently, thus, LC-NMR,
CE-NMR and other coupling techniques can be very convenient
[111,115]. Su et al. [116] elucidated and identiﬁed ﬁve phase I
metabolites and ten phase II metabolites of isobavachalcone in rat
bile using LC-ESI-MSn and LC-NMR method, because simulta-
neously using LC-MS and LC-NMR can supply valuable information
on chemical structure and molecular weight of compounds [117].
3.6. Immunoassay
Immunoassay is based on the speciﬁc binding reaction between
antigen and antibody (Ab). It is usually used in qualitative and
quantitative analysis of biological samples, such as blood, saliva,
urine, as well as hormones and cytokines. As Abs are chiral mo-
lecules and the binding between chiral drugs and Abs may involve
stereoselective interactions, Abs have the potential to split drug
enantiomers [118].
Stereoselective immunoassay is becoming increasingly im-
portant in pharmaceutical analysis, especially in chiral analysis.
There are many types of stereoselective immunoassays, such as
radioimmunoassay, enzyme-linked immunosorbent assay, and
ﬂuorescent immunoassay [119]. Stereoselective immunoassay is
sensitive, speciﬁc and fast [120]. Once the method is established, a
large number of samples can be measured conveniently. What is
more, due to the high speciﬁcity of the antigen–antibody reaction,
the enantiomers can be determined directly from complex biolo-
gical samples [121].
However, stereoselective immunoassay is largely neglected in
the application of chiral drugs analysis. The rapid development of
chiral chromatography may be one of the reasons, but the draw-
backs of immunoassay are likely the main reasons. Since each
chiral drug needs a speciﬁc antibody, the development of a new
immunoassay method becomes complex and time-consuming. To
develop a new enantioselective immunoassay, high stereoselective
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chiral compounds, different chiral Abs need to be prepared and
their ability of chiral recognition needs to be evaluated, and then
the immune-reagent needs to be designed. However, it is still
primarily based on the immunochemist's experiences and a “trial
and error” approach due to the lack of understanding of chiral
interactions between haptens and antibodies [46]. Antibodies may
react with compounds with structures similar to target com-
pounds, such as drug metabolites. If these issues can be overcome,
immunoassay is expected to be applied to preliminary screening
and clinical tests.4. Conclusion
Metabolism is the most important process in drug disposition
and is the most relevant process in stereoselectivity [1,122].
Therefore, stereoselective metabolic pathways inﬂuence the
pharmacological activities, tolerability, safety, and bioavailability
of drugs directly. Chiral inversion, a type of substrate–product
stereoselectivity, is a phenomenon worth noting, especially when
one of the enantiomers has signiﬁcant toxicity and side effects. In
addition, due to the participation of enzymes, enantiomers cata-
lyzed by different enzymes can cause different kinds of drug–drug
interactions. However, the stereoselective metabolic process is so
complex that only the methods of chiral recognition can make
metabolic pathway clear. Consequently, stereoselectivity assessing
methods in drug metabolism are of great relevance to pharma-
ceutical R&D and the rational use in clinic.
Nowadays, various methods are used for stereoselectivity as-
sessing in drug metabolism. Chromatographic methods are still
the most popular techniques, including HPLC, GC, SFC, and CE. The
limitations of indirect methods are that they are applicable to
some speciﬁc samples with functional groups to be derivatized or
form complex with a chiral selector [62,64]. Direct methods
achieved by CSPs are used more frequently due to their elegant
and simple approaches, but CSPs are expensive. Furthermore, CSPs
of CE have poor repeatability, which has been one of the problems
hindering the development of CE. Consequently, high selectivity
and universal CSPs still need to be developed. Chromatographic
techniques are usually coupled to UV, FL and MS. However, chiral
drugs and their metabolites are usually at too low a concentration
in complex biological samples to meet the detection limits of UV
or FL. Although MS is highly sensitive and speciﬁc, the matrix
interference is still a challenge to overcome.
In addition, NMR and immunoassay used in chiral analysis are
worth noting. For example, NMR can be used in structure eluci-
dation, which is useful in analyzing metabolites with unknown
structures. Immunoassay is expected to be applied to preliminary
screening and clinical tests, if the problem of how to establish a
new enantioselective immunoassay simply can be solved. Ad-
ditionally, recombinant antibodies may improve the repeatability
of immunoassay.
Compared with typical achiral assessing methods, although
stereoselectivity assessing methods in drug metabolism face more
challenges, the optimization of existing techniques or tandem
techniques may solve these problems.Acknowledgments
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